Anti-CD252 (OX40L) (Human) mAb

  • Applications
    • FCM
  • Target OX40L/CD252
  • Host Species Mouse
  • Species Reactivities Human
  • Code # D126-3
  • Size 100 μg
  • Price


OX40 ligand (OX40L, also known as CD252/gp34/CD134L) is a 34 kDa of type II membrane protein. OX40L, a member of the tumor necrosis factor (TNF) superfamily, is expressed on activated B cells and antigen presenting cells. OX40L interacts with OX40 antigen (CD134/TNFRSF4/ACT35) expressed predominantly on activated T cells to increase proliferation and IL-2 production. OX40/OX40L interaction provides a costimulatory signal, resulting in enhanced T cell proliferation and cytokine production. Then, cell proliferation and immunoglobulin secretion in activated B cells are enhanced. Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus to be characterized, and it is implicated in the pathogenesis of adult T-cell leukemia (ATL). It is known that HTLV-1-infected cells express various costimulatory molecules such as CD80, CD86, CD40 and OX40L.
  • Antibody Type:
  • Application:
  • Clone Number:
  • Concentration:
    1 mg/mL
  • Conjugate:
  • Description:
    Monoclonal antibody of 100 μg targeting OX40L/CD252 for FCM.
  • Formulation:
    100 μg IgG in 100 μl volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained.
  • Gene ID (Human):
  • Gene ID (Mouse):
  • Host Species:
  • Immunogen:
    Glycoprotein was purified using lenti-lectin column than MT-2 cell culture supernatant
  • Isotype:
  • Product Type:
  • Reactivity:
    This antibody reacts with human CD252 antigen on Flow cytometry.
  • Research Area:
    Cell Biology
  • Short Description:
    OX40L/CD252 Monoclonal Antibody.
  • Size:
    100 μg
  • Species Reactivity:
  • Storage Temperature:
  • Target:
  1. Biagi, E., et al., Blood 105, 2436-2442 (2005)
  2. Hanna, J., et al., J. Immunol. 173, 6547-6563 (2004)
  3. Kashiwakura, J., et al., J. Immunol. 173, 5247-5257 (2004)
  4. Wang, Q., et al., Tissue Antigens 64, 566-574 (2004)
  5. Takahashi, Y., et al., J. Virol. 75, 6748-6757 (2001)
  6. Tanaka, Y., et al., Int. J. Cancer 36, 549-555 (1985)